ESC CVD Pregnancy 2025 — 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy
European Society of Cardiology, 2025
Use a Pregnancy Heart Team for women with significant cardiovascular disease and apply pregnancy-specific guidance to heart failure, peripartum cardiomyopathy, anticoagulation, arrhythmia, aortopathy, pulmonary hypertension, and acute cardiovascular emergencies. PPCM therapy should distinguish pregnancy from postpartum pharmacology and individualize bromocriptine, anticoagulation, and mechanical support.
Clinical Context & Relevant Topics (4)
Disease ReferenceMaternal physiology, preeclampsia/eclampsia, HELLP vs AFLP, postpartum hemorrhage (MTP/TXA), peripartum cardiomyopathy, and arrest.
Primary pump failure, SCAI staging (A–E), PAC hemodynamics (CPO, PAPi), inotrope selection, emergent revascularization, and mechanical circulatory support.
Hemodynamic phenotypes (SCAPE vs ADHF vs Cardiogenic Shock), non-invasive positive pressure ventilation, high-dose vasodilator algorithms, loop diuretics, and sequential nephron blockade.
Hemodynamic classification, right ventricular afterload reduction, selective pulmonary vasodilation, and pulmonary hypertensive crisis management.